Stephen R. Hammes
YOU?
Author Swipe
View article: Islet-intrinsic sex differences in inflammatory signaling contribute to autoimmune diabetes susceptibility
Islet-intrinsic sex differences in inflammatory signaling contribute to autoimmune diabetes susceptibility Open
Whereas most autoimmune diseases exhibit female predominance, type 1 diabetes (T1D) occurs more frequently in males after puberty, suggesting a role for sex hormones in disease modification. Because islet β cells actively shape local immun…
View article: SUN-308 The Combinatory Effects of Estradiol and Tumor Derived Factors on Myeloid Cell Differentiation in Lymphangioleiomyomatosis (LAM)
SUN-308 The Combinatory Effects of Estradiol and Tumor Derived Factors on Myeloid Cell Differentiation in Lymphangioleiomyomatosis (LAM) Open
Disclosure: T. Henson: None. M. Wines-Samuelson: None. R. Myers: None. S.R. Hammes: None. Lymphangioleiomyomatosis (LAM) is a rare multisystemic disease associated with the development of lung cysts caused by small smooth muscle cell tumor…
View article: SUN-215 In-vitro Insulin Treatment of Human Granulosa-like Tumor Cells Results in Insulin Resistance, and May Serve as a Model for the Insulin Resistance Seen in Polycystic Ovary Syndrome (PCOS)
SUN-215 In-vitro Insulin Treatment of Human Granulosa-like Tumor Cells Results in Insulin Resistance, and May Serve as a Model for the Insulin Resistance Seen in Polycystic Ovary Syndrome (PCOS) Open
Disclosure: H. Han: None. K. Vann: None. A. Weidner: None. S.R. Hammes: None. O. Astapova: None. Background: Polycystic ovarian syndrome (PCOS) is characterized by hyperandrogenism and insulin resistance. Previous studies have demonstrated…
View article: SUN-303 Glycoprotein non-metastatic melanoma protein B (GPNMB) mitigates TSC2 null tumor growth and metastasis in Lymphangioleiomyomatosis
SUN-303 Glycoprotein non-metastatic melanoma protein B (GPNMB) mitigates TSC2 null tumor growth and metastasis in Lymphangioleiomyomatosis Open
Disclosure: R. Myers: None. K. Camacho: None. T. Henson: None. M. Wines-Samuelson: None. E. Gibbons: None. S.R. Hammes: None. Lymphangioleiomyomatosis (LAM) is a multisystemic disease almost exclusively found in genetic females. Patients e…
View article: Estrogen Receptor α (ERα) Signaling and Tumor Cell-Derived Factors Mediate Pro-Tumor Neutrophil Activation in the Setting of Lymphangioleiomyomatosis (LAM)
Estrogen Receptor α (ERα) Signaling and Tumor Cell-Derived Factors Mediate Pro-Tumor Neutrophil Activation in the Setting of Lymphangioleiomyomatosis (LAM) Open
Lymphangioleiomyomatosis (LAM), is a rare disease characterized by the abnormal proliferation of smooth muscle-like cells containing tuberous sclerosis complex (TSC) gene mutations. This proliferation leads to tumor formation and cyst deve…
View article: 9308 GPNMB Promotes Tumor Growth and is a Biomarker for Lymphangioleiomyomatosis (LAM)
9308 GPNMB Promotes Tumor Growth and is a Biomarker for Lymphangioleiomyomatosis (LAM) Open
Disclosure: E. Gibbons: None. M. Taya: None. H. Wu: None. S. Lopa: None. J. Moss: None. E.P. Henske: None. F.X. McCormack: None. S.R. Hammes: None. Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease affecting almost …
View article: 7908 GPNMB Promotes Tumor Growth And Is A Biomarker For Lymphangioleiomyomatosis (LAM)
7908 GPNMB Promotes Tumor Growth And Is A Biomarker For Lymphangioleiomyomatosis (LAM) Open
Disclosure: E. Gibbons: None. M. Taya: None. H. Wu: None. S. Lopa: None. J. Moss: None. E.P. Henske: None. F.X. McCormack: None. S.R. Hammes: None. Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease affecting almost …
View article: 8636 Characterization Of The Role Of Neutrophils In Promoting Progression Of Lymphangioleiomyomatosis
8636 Characterization Of The Role Of Neutrophils In Promoting Progression Of Lymphangioleiomyomatosis Open
Disclosure: T.R. Henson: None. B. Minor: None. S.R. Hammes: None. Lymphangioleiomyomatosis (LAM) is a rare, multisystemic disease that is associated with cystic lung destruction. LAM is caused by small smooth muscle cell-like tumors throug…
View article: 7409 Estrogen Receptor a (ERa) Signaling Mediates Pro-Tumor Neutrophil Activation in the Setting of Lymphangioleiomyomatosis (LAM)
7409 Estrogen Receptor a (ERa) Signaling Mediates Pro-Tumor Neutrophil Activation in the Setting of Lymphangioleiomyomatosis (LAM) Open
Disclosure: K.E. O'Leary: None. E. Gibbons: None. B.M. Minor: None. T. Henson: None. S.R. Hammes: None. Lymphangioleiomyomatosis (LAM), is a rare disease marked by the irregular proliferation of smooth muscle-like cells containing tuberous…
View article: 8636 Characterization of the Role of Neutrophils in Promoting Progression of Lymphangioleiomyomatosis
8636 Characterization of the Role of Neutrophils in Promoting Progression of Lymphangioleiomyomatosis Open
Disclosure: T.R. Henson: None. B. Minor: None. S.R. Hammes: None. Lymphangioleiomyomatosis (LAM) is a rare, multisystemic disease that is associated with cystic lung destruction. LAM is caused by small smooth muscle cell-like tumors throug…
View article: 9308 GPNMB Promotes Tumor Growth And Is A Biomarker For Lymphangioleiomyomatosis (LAM)
9308 GPNMB Promotes Tumor Growth And Is A Biomarker For Lymphangioleiomyomatosis (LAM) Open
Disclosure: E. Gibbons: None. M. Taya: None. H. Wu: None. S. Lopa: None. J. Moss: None. E.P. Henske: None. F.X. McCormack: None. S.R. Hammes: None. Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease affecting almost …
View article: 7908 GPNMB Promotes Tumor Growth and is a Biomarker for Lymphangioleiomyomatosis (LAM)
7908 GPNMB Promotes Tumor Growth and is a Biomarker for Lymphangioleiomyomatosis (LAM) Open
Disclosure: E. Gibbons: None. M. Taya: None. H. Wu: None. S. Lopa: None. J. Moss: None. E.P. Henske: None. F.X. McCormack: None. S.R. Hammes: None. Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease affecting almost …
View article: 7409 Estrogen Receptor a (ERa) Signaling Mediates Pro-Tumor Neutrophil Activation In The Setting of Lymphangioleiomyomatosis (LAM)
7409 Estrogen Receptor a (ERa) Signaling Mediates Pro-Tumor Neutrophil Activation In The Setting of Lymphangioleiomyomatosis (LAM) Open
Disclosure: K.E. O'Leary: None. E. Gibbons: None. B.M. Minor: None. T. Henson: None. S.R. Hammes: None. Lymphangioleiomyomatosis (LAM), is a rare disease marked by the irregular proliferation of smooth muscle-like cells containing tuberous…
View article: Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis
Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis Open
Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease affecting almost exclusively female-sexed individuals. The cysts represent regions of lung destruction caused by smooth muscle tumors containing mutations in one of …
View article: From Fundamentals to the Clinic: Advancing Obesity Research in Endocrinology
From Fundamentals to the Clinic: Advancing Obesity Research in Endocrinology Open
View article: FRI613 Sex Differences In Human Islet Transcriptional Responses To Inflammation
FRI613 Sex Differences In Human Islet Transcriptional Responses To Inflammation Open
Disclosure: K.L. Webster: None. W. Wu: None. B. Webb-Robertson: None. E. Nakayasu: None. S. Sarkar: None. C. Evans-Molina: None. S.A. Tersey: None. J. Enriquez: None. S.R. Hammes: None. R.G. Mirmira: None. Higher female incidence of autoim…
View article: THU551 Glycoprotein-NMB (GPNMB) Is A Potential Lymphangioleiomyomatosis (LAM) Therapeutic Target And Biomarker
THU551 Glycoprotein-NMB (GPNMB) Is A Potential Lymphangioleiomyomatosis (LAM) Therapeutic Target And Biomarker Open
Disclosure: E. Gibbons: None. S.R. Hammes: None. Lymphangioleiomyomatosis (LAM) is a rare, progressive, destructive cystic lung disease affecting almost exclusively female-sexed individuals. Mutations in the tuberous sclerosis (TSC1 or TSC…
View article: Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet Open
Graphical abstract Abstract Lymphangioleiomyomatosis (LAM) is a cystic lung disease found almost exclusively in genetic females and caused by small clusters of smooth muscle cell tumors containing mutations in one of the two tuberous scler…
View article: Estradiol Augments Tumor-Induced Neutrophil Production to Promote Tumor Cell Actions in Lymphangioleiomyomatosis Models
Estradiol Augments Tumor-Induced Neutrophil Production to Promote Tumor Cell Actions in Lymphangioleiomyomatosis Models Open
Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease caused by smooth muscle cell-like tumors containing tuberous sclerosis (TSC) gene mutations and found almost exclusively in females. Patient studies suggest LAM progression is es…
View article: Figure S2 from Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase
Figure S2 from Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase Open
High power image of neutrophil elastase localization in a xenograft.
View article: Figure S2 from Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase
Figure S2 from Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase Open
High power image of neutrophil elastase localization in a xenograft.
View article: Figure S1 from Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase
Figure S1 from Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase Open
Depletion of MDSCs suppresses prostate cancer xenograft proliferation.
View article: Data from Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase
Data from Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase Open
Tissue infiltration and elevated peripheral circulation of granulocytic myeloid-derived cells is associated with poor outcomes in prostate cancer and other malignancies. Although myeloid-derived cells have the ability to suppress T-cell fu…
View article: Supplementary Figure 3 from Epigenetic Suppression of SERPINB1 Promotes Inflammation-Mediated Prostate Cancer Progression
Supplementary Figure 3 from Epigenetic Suppression of SERPINB1 Promotes Inflammation-Mediated Prostate Cancer Progression Open
Supplementary Figure 3. Epigenetic repression of endogenous NE inhibitors in LNCaP cells.
View article: Figure S1 from Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase
Figure S1 from Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase Open
Depletion of MDSCs suppresses prostate cancer xenograft proliferation.
View article: Data from Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase
Data from Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase Open
Tissue infiltration and elevated peripheral circulation of granulocytic myeloid-derived cells is associated with poor outcomes in prostate cancer and other malignancies. Although myeloid-derived cells have the ability to suppress T-cell fu…
View article: Supplementary Figure 3 from Epigenetic Suppression of SERPINB1 Promotes Inflammation-Mediated Prostate Cancer Progression
Supplementary Figure 3 from Epigenetic Suppression of SERPINB1 Promotes Inflammation-Mediated Prostate Cancer Progression Open
Supplementary Figure 3. Epigenetic repression of endogenous NE inhibitors in LNCaP cells.
View article: Figure S1 from Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase
Figure S1 from Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase Open
High CD33 expression predicts poor outcomes in prostate cancer patients.
View article: Supplementary Figure 2 from Epigenetic Suppression of SERPINB1 Promotes Inflammation-Mediated Prostate Cancer Progression
Supplementary Figure 2 from Epigenetic Suppression of SERPINB1 Promotes Inflammation-Mediated Prostate Cancer Progression Open
Supplementary Figure 2. EGF does not induce SERPINB1 expression in prostate cancer cells.
View article: Figure S1 from Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase
Figure S1 from Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase Open
High CD33 expression predicts poor outcomes in prostate cancer patients.